Inventor
Vadim Kraynov
Inventor
San Diego, CA, US
Overview
Patents· 26 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides28%
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C12NMicroorganisms or enzymes12%
Y02ATechnologies for adaptation to climate change12%
C07DHeterocyclic compounds2%
PatentTitleYear
10,961,291Modified FGF-21 polypeptides and their uses202110,954,270Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives202110,751,391Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid202010,702,588Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain202010,377,805Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses201910,253,083Therapeutic uses of modified relaxin polypeptides201910,138,283Modified bovine G-CSF polypeptides and their uses20189,975,936Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids20189,962,450Method of treating heart failure with modified relaxin polypeptides20189,938,333Modified leptin polypeptides and their uses20189,796,754'Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives'20179,567,386'Therapeutic uses of modified relaxin polypeptides'20179,517,273'Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids'20169,452,222'Nucleic acids encoding modified relaxin polypeptides'20169,079,971'Modified FGF-21 polypeptides comprising non-naturally occurring amino acids'20158,946,148'Modified insulin polypeptides and their uses'20158,735,539'Relaxin polypeptides comprising non-naturally encoded amino acids'20148,691,940'Relaxin polypeptides comprising non-naturally encoded amino acids'20148,383,365'Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives'20138,329,869'Modified interferon beta polypeptides and their uses'20128,114,630'Modified interferon beta polypeptides and their uses'20128,093,356'Pegylated human interferon polypeptides'20128,012,931'Modified FGF-21 polypeptides and their uses'20117,745,377'Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation'20107,662,644'Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation'20107,176,037'Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation'2007Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2007–2021Based in San Diego, CA, US· patent location history
2011–2021Patents assigned to AMBRX INC (22)· patent assignee history
2012–2018Patents assigned to KRAYNOV VADIM (9)· patent assignee history
2012–2018Patents assigned to KNUDSEN NICK (8)· patent assignee history
2012–2018Patents assigned to PINKSTAFF JASON (6)· patent assignee history
2012–2015Patents assigned to HAYS PUTNAM ANNA-MARIA A (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AMBRX INC | 22 | 2011–2021 |
| KRAYNOV VADIMself | 9 | 2012–2018 |
| KNUDSEN NICK | 8 | 2012–2018 |
| PINKSTAFF JASON | 6 | 2012–2018 |
| HAYS PUTNAM ANNA-MARIA A | 4 | 2012–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 26 | 2007–2021 |